Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Lymphoid 1Breast 1

Conditions

Lymphoma 549Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Lymphoma, Non-Hodgkin 437Lymphoma, Follicular 405Lymphoma, Large B-Cell, Diffuse 392Leukemia, Lymphocytic, Chronic, B-Cell 392Lymphoma, B-Cell 248Lymphoma, Mantle-Cell 224Hodgkin Disease 209Recurrence 205Leukemia, Myeloid, Acute 199Leukemia 196Multiple Myeloma 185Burkitt Lymphoma 185Lymphoma, B-Cell, Marginal Zone 170Neoplasms 153Myelodysplastic Syndromes 134Hematologic Neoplasms 115Waldenstrom Macroglobulinemia 103Lymphoma, T-Cell, Peripheral 86Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, T-Cell 82Lymphoma, T-Cell, Cutaneous 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Mycosis Fungoides 57Leukemia, Biphenotypic, Acute 55Breast Neoplasms 55Leukemia, B-Cell 52Myeloproliferative Disorders 50Lymphoproliferative Disorders 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × Lymphoid × 1 year × Clear all
NCT06487624 2026-04-13

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

FBD Biologics Limited

Phase 1 Recruiting
50 enrolled
Lymphoid

Camurati-Engelmann Syndrome, Hodgkin Disease, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡